Rep. Eliot Engel (D-NY) made a brief appearance Tuesday at a Congressional briefing, hosted by several TB advocacy organizations, highlighting tuberculosis and its continuation as a global health threat. He called the fact that TB hasn’t been eradicated “a sin,” and then briefly announced the newly formed U.S. House of Representatives TB Elimination Caucus – […]
Otsuka Pharmaceuticals is the top private funder of tuberculosis (TB) research and drug development in the world. Last year, Otsuka established a Geneva-based subsidiary – Otsuka SA – to serve as “the company’s central operations for developing and implementing public health policies and corporate social responsibility programs in connection with its global TB program,” according to the company’s website.
As part of our reporting in advance of World TB Day on Saturday (March 24), Science Speaks interviewed Patrizia Carlevaro, PhD, the leader of Otsuka SA, to discuss Otsuka’s latest research to address drug-resistant forms of TB, the world’s emerging tuberculosis “hotspots,” and other efforts by the subsidiary organization to tackle TB.
HIV
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
Tuberculosis
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
With a report showing that 2018 yielded the highest case numbers seen so far of a paralyzing condition largely among children who had been sick with […]